Novo Nordisk is moving Amycretin to Phase 3 trials after early data showed up to 24.3% weight loss. A higher Wegovy dose also delivered 21% weight loss in a separate study. The company aims to expand obesity treatments and regain investor momentum amid a stock drop. CagriSema also showed strong Phase 3 results.